Isarna Therapeutics

Isarna Therapeutics is a clinical-stage biotechnology company headquartered in Munich, Germany. Isarna Therapeutics is dedicated to developing selective TGF-β inhibitors for the effective treatment of ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination approaches to surpass clinical responses and improve patient outcomes.